The estimated Net Worth of Shankar Musunuri is at least $5.17 Milion dollars as of 17 January 2023. Dr Musunuri owns over 100,000 units of Ocugen Inc stock worth over $2,863,379 and over the last 5 years he sold OCGN stock worth over $1,524,900. In addition, he makes $780,673 as Co-Founder a Chairman & CEO at Ocugen Inc.
Dr has made over 16 trades of the Ocugen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of OCGN stock worth $51,000 on 17 January 2023.
The largest trade he's ever made was buying 406,000 units of Ocugen Inc stock on 11 December 2019 worth over $158,340. On average, Dr trades about 90,016 units every 49 days since 2019. As of 17 January 2023 he still owns at least 2,327,950 units of Ocugen Inc stock.
You can see the complete history of Dr Musunuri stock trades at the bottom of the page.
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. is the Co-Founder, Chairman & CEO at Ocugen Inc.
As the Co-Founder a Chairman & CEO of Ocugen Inc, the total compensation of Dr D at Ocugen Inc is $780,673. There are no executives at Ocugen Inc getting paid more.
Dr D is 57, he's been the Co-Founder a Chairman & CEO of Ocugen Inc since . There are 7 older and 9 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
Shankar's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang a Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: